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Abstract
Introduction Acquired angioedema (AAE), an acquired deficiency of C1esterase inhibitor, is a medically treatable condition
which can cause severe abdominal pain mimicking an acute surgical abdomen. This disorder is strongly associated with
chronic lymphocytic leukemia (CLL) and other indolent lymphoplasmacytic disorders.
Discussion We describe a patient with known CLL who developed incapacitating, recurrent severe abdominal pains,
culminating in partial bowel resection. Signs, symptoms, laboratory and pathologic findings demonstrated AAE.
Conclusion Wider appreciation of the possibility of AAE, particularly in patients with lymphoproliferative disorders, could
lead to preventive therapy and spare unnecessary surgery. This is more important now that more effective medical therapies
are available.
Keywords Acquired angioedema.Chronic lymphocytic
leukemia.Autoimmunity.C1 inhibitor deficiency
Introduction
Acquired angioedema (AAE) is due to acquired deficiency
of C1 inhibitor (C1Inh), resulting in excessive complement
and bradykinin activities. Blood vessel permeability is
increased; thus, angioedema occurs. Just as with hereditary
angioedema (hereditary C1Inh deficiency; HAE), common
clinical manifestations are skin swelling, laryngeal edema,
and/or abdominal pain.
1,2
AAE often occurs in the context of lymphoplasma-
cytic disorders, such as monoclonal gammopathy of
unknown significance (MGUS), non-Hodgkin’sl y m p h o -
ma, or chronic lymphocytic leukemia (CLL).
1,3 Among
32 patients with AAE, Castelli found that 13 (40%) had
MGUS and 9 (28%) had lymphoproliferative disease.
3
Therefore, all cases of AAE should be evaluated for the
possibility of underlying lymphoplasmacytic disorder.
Conversely, when patients with known lymphoprolifer-
ative disease manifest compatible symptoms, AAE should
be expeditiously considered. This is important because
AAE can be effectively treated medically, but delayed
diagnosis can lead to unnecessary diagnostic procedures,
therapeutic interventions, or life-threatening complications,
well-illustrated by our case.
Case Presentation
A 78-year-old woman with atherosclerotic vascular
disease was transferred to our hospital with abdominal
pain and underwent emergent laparotomy. One year
earlier, she had been diagnosed with Rai Stage I CLL
which had been observed without treatment. Two
months earlier, she presented with severe abdominal
pain, nausea, and vomiting. Over the next 8 weeks, she
had six emergency room and/or hospital admissions for
identical symptoms. The episodes left the patient weak
and incapacitated. Pains would begin at rest in the
lower abdomen, spread to the upper abdomen, described
as “gas-like”, non-radiating, constant. There was no
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Subsequent vomiting was nonbloody, nonbilious, and
did not relieve the pain. Episodes resolved spontane-
o u s l yw i t h i n2 –3 days with intravenous hydration and
pain control. Extensive evaluation included colonoscopy,
endoscopic retrograde cholangiopancreatography, mag-
netic resonance angiography, and abdominal aortogra-
phy. Benign colon polyps and small gallstones were
removed, mesenteric stenoses ruled out, yet pains
recurred unabated. She had lost 12 lbs. There was no
dysphagia, change in bowel habits, GI bleeding, fever,
or sweats. Medications included baby aspirin, clopidogrel,
benazepril, hydrochlorothiazide, and glipizide.
Physical examination on transfer revealed blood pressure
130/88 mmHg, pulse 88 beats per minute, respiratory rate
20 cycles per minute, pulse oximetry of 95% on ambient
air, and temperature 97.0°F. The patient was in acute
distress due to abdominal pain. Left cervical and axillary
lymph nodes were enlarged to 1.5 cm in diameter.
Cardiopulmonary examination was unremarkable. Abdo-
men was slightly distended, diffusely exquisitely tender
with guarding and rebound. Bowel sounds were hypoac-
tive. Rectal examination showed guaiac-negative brown
stool.
Hemoglobin was 18.1 g/dL, hematocrit 55%, platelets
146×10
9/L, and leukocytes elevated to 34,500 cells/μL
with 47% neutrophils and 48% lymphocytes. Chemistries
and liver function tests were normal. Abdominal X-ray
showed no free air, nor air-fluid levels. CTscan of abdomen
and pelvis with IV contrast showed multiple abnormal
loops of small bowel with contrast-enhanced bowel wall
edema (Fig. 1a).
At laparotomy, massively swollen small bowel was
encountered and resected. Pathologic examination revealed
massive submucosal edema (Fig. 1b). There was no
leukemic infiltration visible.
A hematology consultant, called postoperatively,
suspected AAE. C4 was 3 mg/dL (normal 17–46), C3
66 mg/dL (85–200), and C1Inh activity reportedly 83%
(68–200%). Serum protein electrophoresis revealed two
faint bands immunofixing as monoclonal IgM kappa
and IgG kappa. Chlorambucil was started for CLL and
danazol to raise C1Inh. Lymphocytosis and lymphade-
nopathy improved and C1Inh activity increased to
110%. Over 3 years of follow-up, abdominal symptoms
never recurred.
Discussion
Approximately 145 cases have been reported of AAE,
3
and this is one of four cases that we have diagnosed in the
last decade with abdominal pains from AAE with
associated CLL. Table 1 shows characteristics of patients
with CLL and AAE we have seen (some briefly mentioned
in a prior report).
4 This is our only case to undergo
surgery, allowing unique and dramatic demonstration of
massive bowel edema visible radiographically, on surgical
inspection and on histopathology. An initial C1Inh activity
was reported low normal, but there can be no doubt about
the diagnosis based on radiologic/surgical/histologic find-
ings, further laboratory results, and the clinical course.
Characteristic are very low C4 level and low C3;
diagnostic recommendations currently add C1q and anti-
C1Inh antibody levels. Autoantibody is demonstrable in
up to 70% with AAE.
1 Our patient had monoclonal
gammopathy, which frequently corresponds to the C1Inh
autoantibody. Patients with the hereditary form (HAE)
Fig. 1 a CT scan of abdomen and pelvis with intravenous contrast
shows several abnormal loops of small bowel with a target appearance
indicating bowel wall edema. b A section of small bowel shows
massive submucosal edema. There is no infiltration of the wall by
lymphocytes
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2264 J Gastrointest Surg (2011) 15:2262–2266usually manifest before age 20 and give a family history
of symptoms. In all our patients with CLL and AAE,
chemotherapy and androgens increased C1Inh and produced
durable remission.
Angioedema should be borne in mind among “medical”
illnesses that can mimic acute surgical abdomen, along with
such other disorders as porphyria, Familial Mediterranean
fever and sickle cell disease (Fig. 2). One may need to
discern whether a true surgical emergency might supervene
even when one of these disorders is present. Our patient
had typical symptoms of acute bowel edema, including
diffuse abdominal pain, occasionally rebound tenderness
and vomiting, with spontaneous resolution within 1–
5 days.
1,2 Some patients with AAE have cutaneous or
upper respiratory edema in addition, or instead of, bowel
symptoms. Because of cardiovascular comorbidities, there
was a high suspicion for ischemic bowel in our patient, but
radiography and endoscopy did not support this. In the
differential diagnosis, angiotensin-converting enzyme
inhibitors rarely precipitate angioedema, but our patient
had taken benazepril many years and continued it without
incident after AAE therapy.
In 2009, the US FDA approved the C1Inh concentrate
BerinertP®andthekallikreininhibitorecallantide(Kalbitor®)
for treatment of acute attacks, and the C1Inh concentrate
Cinryze® for prophylaxis in severely affected patients.
5
Fresh frozen plasma can be given when these are
unavailable. C1Inh concentrates are highly safe and
effective; the standard of care for decades in other
countries, but US approval was delayed by concerns of
virus transmissibility.
1,5–9 Doses used in the clinical HAE
trials may need to be higher for AAE because of increased
enzyme clearance. Ecallantide is subcutaneous, facilitating
patient self-administration out of hospital. A bradykinin
B2 receptor antagonist icatibant (Firazyr®) is under
investigation. For long-term control, the underlying cause
should be addressed, CLL in our case. Commonly used for
prophylaxis are anti-fibrinolytic drugs or the attenuated
androgen danazol, which increases C1Inh synthesis at low
cost.
10
Symptoms & Signs
Recurrent episodes of nausea, vomiting, abdominal pain or diarrhea
May have rebound tenderness on exam
Spontaneous recovery in 1-5 days
CT scan with PO/IV contrast: may reveal bowel wall edema- (“donut sign”)
May have concurrent or history of cutaneous or upper respiratory tract edema 
Especially consider Acquired AE when 
Comorbid lymphoproliferative disorder
e.g. CLL, MGUS, Lymphoma etc.
Onset of Age > 40 years old
No family history of Hereditary Angioedema(HAE)
Confirm diagnosis with 
Radioloy to exibitbowel wall edema and exclude other pathology
Low C1 inh functional activity 
Low or Normal Quantitative C1inh 
Anti-C1 inh autoantibody - Present(70%)
Low C4
Low C1q (Normal in HAE)
Treatment
C1 inh concentrate(BerinertP®) 
Kallikrein inhibitor ecallantide(Kalbitor®)
If not available, Fresh Frozen Plasma
Prophylaxis Acute attack
C1Inh concentrate (Cinryze®) 
Androgen (eg. danazol)
Anti-fibrinolytic drugs (eg. tranexamic acid)
Fig. 2 Algorithm for diagnosis and treatment for suspected AAE
J Gastrointest Surg (2011) 15:2262–2266 2265In conclusion, earlier suspicion for AAE in our known
CLL patient could have spared her the morbidities of
recurrent abdominal pains, hospitalizations, morbid inter-
ventions, and bowel resection. Wider appreciation of this
disorder takes on added importance as our ability to
effectively treat the problem has grown.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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